Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Thomas U. Marron, Anwaar Saeed, Matthias Pinter, Yi‐Hsiang Huang, A. Pillai, Martin Schoenlein, Johann von Felden, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Hong Jae Chon, Wei‐Fan Hsu, Leonardo Brunetti, Carmine Pinto, Melissa Bersanelli, Alessio Cortellini, D.J. Pinato (2023). 111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours. , 20, DOI: https://doi.org/10.1016/j.iotech.2023.100583.
Article7 days agoValidation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
Margherita Rimini, Wonseok Kang, Valentina Burgio, Mara Persano, Tamoko Aoki, Shigeo Shimose, Toshifumi Tada, Takashi Kumada, Takuya Sho, Eleonora Lai, Ciro Celsa, Claudia Campani, Matteo Tonnini, Emiliano Tamburini, Atsushi Hiraoka, Koichi Takaguchi, Naoshi Nishida, Hideki Iwamoto, Ei Itobayashi, Kunihiko Tsuji, Naoya Sakamoto, Toru Ishikawa, Hidenori Toyoda, Masatoshi Kudo, Takumi Kawaguchi, Takeshi Hatanaka, Kazuhiro Nouso, Goki Suda, Giuseppe Cabibbo, Fabio Marra, Angelo Della Corte, Francesca Ratti, Federica Pedica, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini (2022). Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. , 52(12), DOI: https://doi.org/10.1111/hepr.13824.
Article7 days agoReproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda, Ilario Giovanni Rapposelli, Andrea Casadei‐Gardini, Caterina Vivaldi, Susanna V. Ulahannan, Haripriya Andanamala, Bernhard Scheiner, Matthias Pinter, Elena Orlandi, Claudia Angela Maria Fulgenzi, Giulia Francesca Manfredi, Pasquale Lombardi, Antonio D’Alessio, Bernardo Stefanini, Rosanna Villani, Francesca Romana Ponziani, Leonardo Stella, Ornella Carminati, Angela Dalia Ricci, Melina Gonzalez (2025). Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study. , 8(3), DOI: https://doi.org/10.1016/j.jhepr.2025.101685.
Article7 days agoOutcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA trial eligibility: Preliminary results of the international DT-real study.
Ciro Celsa, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Hidenori Toyoda, Susanna V. Ulahannan, Claudia Angela Maria Fulgenzi, Giulia Francesca Manfredi, Antonio D’Alessio, Bernardo Stefanini, Giuseppe Cabibbo, Calogero Cammà, Bernhard Scheiner, Lorenza Rimassa, Robin Kate Kelley, Amit Singal, Ahmed O. Kaseb, Masatoshi Kudo (2025). Outcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA trial eligibility: Preliminary results of the international DT-real study.. , 43(4_suppl), DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.552.
Article7 days agoEfficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D’Alessio, Matthias Pinter, B Scheiner, Nichola Awosika, Leonardo Brunetti, Pasquale Lombardi, Charles Latchford, Pei-Chang Lee, Yi‐Hsiang Huang, Chung‐Yen Lin, Andrea Dalbeni, Arndt Vogel, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Hong Jae Chon, Giuseppe Cabibbo, Fabio Piscaglia, Calogero Cammà, Anjana Pillai, Mario Pirisi, Amit G. Singal, David J. Pinato (2025). Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence. , 7(8), DOI: https://doi.org/10.1016/j.jhepr.2025.101431.
Article7 days ago